Megan B. Sands
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Megan B. Sands has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Jane M. Ingham
2 shared publicationsJanette L. Vardy
Concord Cancer Centre, Concord Repatriation General Hospital, Sydney, Australia
2 shared publicationsMeera Agar
University of Technology Sydney, Sydney, Australia
2 shared publicationsMichael Piza
2 shared publicationsA. Hartshorn
Department of Psychiatry, Concord Hospital, Sydney, Australia
1 shared publicationAndrew Dimitri
Respiratory and Sleep Medicine, Prince of Wales Hospital , Randwick, Australia
1 shared publication
Latest Publications
- Open Access
- 12 September 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (18) , 2275
Psychedelic-Assisted Therapy in Palliative Care—Insights from an International Workshop
Background: Evidence is growing that psychedelic substances have positive effects in the setting of Palliative Care (PC), focusing on special needs in this patient population. After a scoping review of the literature, no published expert recommendations guiding best practice for psychedelic-assisted therapy (PAT) towards the end of life were identified. Objective: To draw conclusions from first-hand experienced professionals on PAT in PC (PATPC). Setting, Design, Participants: An international workshop with experts was held in Wasserfallen, Switzerland. A thematic analysis of a semi-structured, questionnaire-based qualitative study with 13 experts in PC, oncology, psychiatry/psychology, and PAT from Europe, the United States, and Oceania was made. Measurements: The questionnaire was designed to elicit the participant’s perspectives on (A) special considerations on PATPC, (B) specific characteristics of PATPC (versus mental illness), and (C) the relevance of these differences during preparation, substance dosing session, and integration in PATPC. Results: (A) Special Considerations included (non-medicalized) setting, potential need, and possibility to reduce preparation time. (B) Distinguishing characteristics included the patient’s intrinsic motivation for treatment success, the importance of anxiety, depression, and spiritual distress as indications for PATPC, and the importance of sufficient integration of the psychedelic experience into life in the face of limited time due to the life-limiting illness. (C) Flexibility in setting and timing of preparation, choosing the appropriate dosage of the psychedelic substance depending on the patient’s intended focus, low/medium (relational issues), higher for transcendental experiences, considering mental capacity and vulnerability for the individual. In addition, respondents noted that for therapists, knowledge about transcendental states, such as mystical experiences, existential aspects of life-threatening illness, and the role of therapists’ own self-experience/inner work, as well as good knowledge of the theoretical basis for treatment, was highlighted. Conclusions: This study highlights special considerations for PAT PC and could be a first step towards specific treatment recommendations (guidelines) for PATPC.
- 12 September 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (18) , 2275
Open AccessPsychedelic-Assisted Therapy in Palliative Care—Insights from an International Workshop
Background: Evidence is growing that psychedelic substances have positive effects in the setting of Palliative Care (PC), focusing on special needs in this patient population. After a scoping review of the literature, no published expert recommendations guiding best practice for psychedelic-assisted therapy (PAT) towards the end of life were identified. Objective: To draw conclusions from first-hand experienced professionals on PAT in PC (PATPC). Setting, Design, Participants: An international workshop with experts was held in Wasserfallen, Switzerland. A thematic analysis of a semi-structured, questionnaire-based qualitative study with 13 experts in PC, oncology, psychiatry/psychology, and PAT from Europe, the United States, and Oceania was made. Measurements: The questionnaire was designed to elicit the participant’s perspectives on (A) special considerations on PATPC, (B) specific characteristics of PATPC (versus mental illness), and (C) the relevance of these differences during preparation, substance dosing session, and integration in PATPC. Results: (A) Special Considerations included (non-medicalized) setting, potential need, and possibility to reduce preparation time. (B) Distinguishing characteristics included the patient’s intrinsic motivation for treatment success, the importance of anxiety, depression, and spiritual distress as indications for PATPC, and the importance of sufficient integration of the psychedelic experience into life in the face of limited time due to the life-limiting illness. (C) Flexibility in setting and timing of preparation, choosing the appropriate dosage of the psychedelic substance depending on the patient’s intended focus, low/medium (relational issues), higher for transcendental experiences, considering mental capacity and vulnerability for the individual. In addition, respondents noted that for therapists, knowledge about transcendental states, such as mystical experiences, existential aspects of life-threatening illness, and the role of therapists’ own self-experience/inner work, as well as good knowledge of the theoretical basis for treatment, was highlighted. Conclusions: This study highlights special considerations for PAT PC and could be a first step towards specific treatment recommendations (guidelines) for PATPC.
- Open Access
- 14 March 2025
- Published by Springer Nature in European Geriatric Medicine
- Vol. 16 (3) , 793-805
The perspectives on advance care planning of older people with psychotic illnesses and their carers
Purpose: To examine the attitudes, experiences, and perceived facilitators and barriers to Advance Care Planning (ACP), of older people with schizophrenia and other psychotic illness and their carers. Methods: Older people with a psychotic illness and carers were recruited from public mental health services in Sydney, Australia. Semi-structured interviews to explore attitudes, experiences, and perceived barriers and facilitators to ACP were conducted by an external clinician. Consumers’ medical, psychiatric and drug health diagnoses were recorded and they completed cognitive and symptom rating scales. Reflexive thematic analysis was used to analyse the transcripts of interviews, within an interpretive description framework. Results: Thematic saturation was achieved with 12 consumers and 5 carers. Emergent themes from consumer interviews were (i) ‘What is ACP?’; (ii) ‘I have not done ACP because…..’; (iii) ‘I want to do ACP’; (iv) ‘If I was to do ACP I would need..’; and (v) ‘Mental health clinicians have the skills to help me with ACP’. Carer themes included (i) ‘We do not participate in ACP’, (ii) ‘I want to participate in ACP’, and (iii) ‘Key clinician skills are needed’. There was convergence of themes from both groups. Conclusion: This study demonstrates that older people with a psychotic illness can express views regarding ACP, despite ongoing symptoms of psychosis, cognitive impairment and mild–moderate severity of illness. The emergent themes highlight opportunities to intervene to overcome barriers to ACP, including education for both participant groups and clinicians, practical considerations and the need for all to collaborate, including with primary care.
- 14 March 2025
- Published by Springer Nature in European Geriatric Medicine
- Vol. 16 (3) , 793-805
Open AccessThe perspectives on advance care planning of older people with psychotic illnesses and their carers
Purpose: To examine the attitudes, experiences, and perceived facilitators and barriers to Advance Care Planning (ACP), of older people with schizophrenia and other psychotic illness and their carers. Methods: Older people with a psychotic illness and carers were recruited from public mental health services in Sydney, Australia. Semi-structured interviews to explore attitudes, experiences, and perceived barriers and facilitators to ACP were conducted by an external clinician. Consumers’ medical, psychiatric and drug health diagnoses were recorded and they completed cognitive and symptom rating scales. Reflexive thematic analysis was used to analyse the transcripts of interviews, within an interpretive description framework. Results: Thematic saturation was achieved with 12 consumers and 5 carers. Emergent themes from consumer interviews were (i) ‘What is ACP?’; (ii) ‘I have not done ACP because…..’; (iii) ‘I want to do ACP’; (iv) ‘If I was to do ACP I would need..’; and (v) ‘Mental health clinicians have the skills to help me with ACP’. Carer themes included (i) ‘We do not participate in ACP’, (ii) ‘I want to participate in ACP’, and (iii) ‘Key clinician skills are needed’. There was convergence of themes from both groups. Conclusion: This study demonstrates that older people with a psychotic illness can express views regarding ACP, despite ongoing symptoms of psychosis, cognitive impairment and mild–moderate severity of illness. The emergent themes highlight opportunities to intervene to overcome barriers to ACP, including education for both participant groups and clinicians, practical considerations and the need for all to collaborate, including with primary care.
- Open Access
- 15 January 2022
- Published by Springer Nature in European Geriatric Medicine
- Vol. 13 (1) , 33-51
The detection of delirium in admitted oncology patients: a scoping review
Purpose: Delirium leads to poor outcomes for patients and careers and has negative impacts on staff and service provision. Cancer rates in elderly populations are increasing and frequently, cancer diagnoses are a co-morbidity in the context of frailty. Data relating to the epidemiology of delirium in hospitalised cancer patients are limited. With the overarching purpose of improving delirium detection and reducing the morbidity and mortality of delirium in cancer patients, we reviewed the epidemiological data and approach to delirium detection in hospitalised, adult oncology patients. Methods: MEDLINE, EMBASE, CINAHL, PsycINFO, and SCOPUS databases were searched from January 1996 to August 2017. Key concepts were delirium, cancer, inpatient oncology and delirium screening/detection. Results: Of 896 unique studies identified; 91 met full-text review criteria. Of 12 eligible studies, four applied recommended case ascertainment methods to all patients, three used delirium screening tools alone or with case ascertainment tools sub-optimally applied, four used tools not recommended for delirium screening or case ascertainment, one used the Confusion Assessment Method with insufficient information to determine if it met case ascertainment status. Two studies presented delirium incidence rates: 7.8%, and 17% respectively. Prevalence rates ranged from 18–33% for general medical or oncology wards; 42–58% for Acute Palliative Care Units (APCU); and for older cancer patients: 22% and 57%. Three studies reported reversibility; 26% and 49% respectively (APCUs) and 30% (older patients with cancer). Six studies had a low risk of bias according to QUADAS-2 criteria; all studies in the APCU setting were rated at higher risk of bias. Tool selection, study flow and recruitment bias reduced study quality. Conclusion: The knowledge base for improved interventions and clinical care for adults with cancer and delirium is limited by the low number of studies. A clear distinction between screening tools and diagnostic tools is required to provide an improved understanding of the rates of delirium and its reversibility in this population.
- 15 January 2022
- Published by Springer Nature in European Geriatric Medicine
- Vol. 13 (1) , 33-51
Open AccessThe detection of delirium in admitted oncology patients: a scoping review
Purpose: Delirium leads to poor outcomes for patients and careers and has negative impacts on staff and service provision. Cancer rates in elderly populations are increasing and frequently, cancer diagnoses are a co-morbidity in the context of frailty. Data relating to the epidemiology of delirium in hospitalised cancer patients are limited. With the overarching purpose of improving delirium detection and reducing the morbidity and mortality of delirium in cancer patients, we reviewed the epidemiological data and approach to delirium detection in hospitalised, adult oncology patients. Methods: MEDLINE, EMBASE, CINAHL, PsycINFO, and SCOPUS databases were searched from January 1996 to August 2017. Key concepts were delirium, cancer, inpatient oncology and delirium screening/detection. Results: Of 896 unique studies identified; 91 met full-text review criteria. Of 12 eligible studies, four applied recommended case ascertainment methods to all patients, three used delirium screening tools alone or with case ascertainment tools sub-optimally applied, four used tools not recommended for delirium screening or case ascertainment, one used the Confusion Assessment Method with insufficient information to determine if it met case ascertainment status. Two studies presented delirium incidence rates: 7.8%, and 17% respectively. Prevalence rates ranged from 18–33% for general medical or oncology wards; 42–58% for Acute Palliative Care Units (APCU); and for older cancer patients: 22% and 57%. Three studies reported reversibility; 26% and 49% respectively (APCUs) and 30% (older patients with cancer). Six studies had a low risk of bias according to QUADAS-2 criteria; all studies in the APCU setting were rated at higher risk of bias. Tool selection, study flow and recruitment bias reduced study quality. Conclusion: The knowledge base for improved interventions and clinical care for adults with cancer and delirium is limited by the low number of studies. A clear distinction between screening tools and diagnostic tools is required to provide an improved understanding of the rates of delirium and its reversibility in this population.
- 16 February 2021
- Published by SAGE Publications in Palliative Medicine
- Vol. 35 (4) , 683-696
Delirium screening tools validated in the context of palliative care: A systematic review
Delirium is a distressing neuropsychiatric disorder affecting patients in palliative care. Although many delirium screening tools exist, their utility, and validation within palliative care settings has not undergone systematic review. To systematically review studies that validate delirium screening tools conducted in palliative care settings. Systematic review with narrative synthesis (PROSPERO ID: CRD42019125481). A risk of bias assessment via Quality Assessment Tool for Diagnostic Accuracy Studies-2 was performed. Five electronic databases were systematically searched (January 1, 1982–May 3, 2020). Quantitative studies validating a screening tool in adult palliative care patient populations were included. Studies involving alcohol withdrawal, critical or perioperative care were excluded. Dual-reviewer screening of 3749 unique titles and abstracts identified 95 studies for full-text review and of these, 17 studies of 14 screening tools were included (n = 3496 patients). Data analyses revealed substantial heterogeneity in patient demographics and variability in screening and diagnostic practices that limited generalizability between study populations and care settings. A risk of bias assessment revealed methodological and reporting deficits, with only 3/17 studies at low risk of bias. The processes of selecting a delirium screening tool and determining optimal screening practices in palliative care are complex. One tool is unlikely to fit the needs of the entire palliative care population across all palliative care settings. Further research should be directed at evaluating and/or adapting screening tools and practices to fit the needs of specific palliative care settings and populations.
- 16 February 2021
- Published by SAGE Publications in Palliative Medicine
- Vol. 35 (4) , 683-696
Delirium screening tools validated in the context of palliative care: A systematic review
Delirium is a distressing neuropsychiatric disorder affecting patients in palliative care. Although many delirium screening tools exist, their utility, and validation within palliative care settings has not undergone systematic review. To systematically review studies that validate delirium screening tools conducted in palliative care settings. Systematic review with narrative synthesis (PROSPERO ID: CRD42019125481). A risk of bias assessment via Quality Assessment Tool for Diagnostic Accuracy Studies-2 was performed. Five electronic databases were systematically searched (January 1, 1982–May 3, 2020). Quantitative studies validating a screening tool in adult palliative care patient populations were included. Studies involving alcohol withdrawal, critical or perioperative care were excluded. Dual-reviewer screening of 3749 unique titles and abstracts identified 95 studies for full-text review and of these, 17 studies of 14 screening tools were included (n = 3496 patients). Data analyses revealed substantial heterogeneity in patient demographics and variability in screening and diagnostic practices that limited generalizability between study populations and care settings. A risk of bias assessment revealed methodological and reporting deficits, with only 3/17 studies at low risk of bias. The processes of selecting a delirium screening tool and determining optimal screening practices in palliative care are complex. One tool is unlikely to fit the needs of the entire palliative care population across all palliative care settings. Further research should be directed at evaluating and/or adapting screening tools and practices to fit the needs of specific palliative care settings and populations.
- Open Access
- 18 January 2021
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-9
“SQiD, the Single Question in Delirium; can a single question help clinicians to detect delirium in hospitalised cancer patients?” running heading Single Question in Delirium” (Bcan-D-20-01665)
Aim: A serious syndrome for cancer in-patients, delirium risk increases with age and medical acuity. Screening tools exist but detection is frequently delayed or missed. We test the ‘Single Question in Delirium’ (SQiD), in comparison to psychiatrist clinical interview. Methods: Inpatients in two comprehensive cancer centres were prospectively screened. Clinical staff asked informants to respond to the SQiD: “Do you feel that [patient’s name] has been more confused lately?”. The primary endpoint was negative predictive value (NPV) of the SQiD versus psychiatrist diagnosis (Diagnostic and Statistics Manual criteria). Secondary endpoints included: NPV of the Confusion Assessment Method (CAM), sensitivity, specificity and Cohen’s Kappa coefficient. Results: Between May 2012 and July 2015, the SQiD plus CAM was applied to 122 patients; 73 had the SQiD and psychiatrist interview. Median age was 65 yrs. (interquartile range 54–74), 46% were female; median length of hospital stay was 12 days (5–18 days). Major cancer types were lung (19%), gastric or other upper GI (15%) and breast (14%). 70% of participants had stage 4 cancer. Diagnostic values were similar between the SQiD (NPV = 74, 95% CI 67–81; kappa = 0.32) and CAM (NPV = 72, 95% CI 67–77, kappa = 0.32), compared with psychiatrist interview. Overall the CAM identified only a small number of delirious cases but all were true positives. The specificity of the SQiD was 87% (74–95) The SQiD had higher sensitivity than CAM (44% [95% CI 41–80] vs 26% [10–48]). Conclusion: The SQiD, administered by bedside clinical staff, was feasible and its psychometric properties are now better understood. The SQiD can contribute to delirium detection and clinical care for hospitalised cancer patients.
- 18 January 2021
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-9
Open Access“SQiD, the Single Question in Delirium; can a single question help clinicians to detect delirium in hospitalised cancer patients?” running heading Single Question in Delirium” (Bcan-D-20-01665)
Aim: A serious syndrome for cancer in-patients, delirium risk increases with age and medical acuity. Screening tools exist but detection is frequently delayed or missed. We test the ‘Single Question in Delirium’ (SQiD), in comparison to psychiatrist clinical interview. Methods: Inpatients in two comprehensive cancer centres were prospectively screened. Clinical staff asked informants to respond to the SQiD: “Do you feel that [patient’s name] has been more confused lately?”. The primary endpoint was negative predictive value (NPV) of the SQiD versus psychiatrist diagnosis (Diagnostic and Statistics Manual criteria). Secondary endpoints included: NPV of the Confusion Assessment Method (CAM), sensitivity, specificity and Cohen’s Kappa coefficient. Results: Between May 2012 and July 2015, the SQiD plus CAM was applied to 122 patients; 73 had the SQiD and psychiatrist interview. Median age was 65 yrs. (interquartile range 54–74), 46% were female; median length of hospital stay was 12 days (5–18 days). Major cancer types were lung (19%), gastric or other upper GI (15%) and breast (14%). 70% of participants had stage 4 cancer. Diagnostic values were similar between the SQiD (NPV = 74, 95% CI 67–81; kappa = 0.32) and CAM (NPV = 72, 95% CI 67–77, kappa = 0.32), compared with psychiatrist interview. Overall the CAM identified only a small number of delirious cases but all were true positives. The specificity of the SQiD was 87% (74–95) The SQiD had higher sensitivity than CAM (44% [95% CI 41–80] vs 26% [10–48]). Conclusion: The SQiD, administered by bedside clinical staff, was feasible and its psychometric properties are now better understood. The SQiD can contribute to delirium detection and clinical care for hospitalised cancer patients.
- 1 September 2017
- Published by European Respiratory Society (ERS)
- Vol. 50 (suppl 61) , PA603
Advance Care Planning (ACP) for end stage respiratory patients identified using the Hospital One year Mortality Rating (HOMR) tool
Background: Advance Care Planning (ACP) results in improved use of resources and patient outcomes. Inadequate ACP undermines self-determination and risks ineffective treatment. We reviewed records of patients enrolled in a respiratory outreach program at a University hospital in Sydney, Australia. At baseline none had an Advance Care Plan in the electronic medical records (eMR). Objectives: To improve end of life planning and outcomes for patients with advanced chronic lung conditions. Methods: We used healthcare redesign methodology including: literature review; process mapping; patient/carer interviews; staff surveys; focus groups; data abstraction and analysis. Five focus areas were identified and solutions mapped. Results: Patients, carers and clinicians were willing to be engaged in ACP. Application of the HOMR tool mapped risk of death within 12 months in this population (n=183, median 13.6%, range 0.2 - 91.1%; 16 patients had a 50% or greater risk). A standardised process was developed colaboratively with the multidisciplinary team comprising changed work practices, evidence based staff training, engagement with primary care and eMR solutions. At 6 months 11 advance care plans were completed. Conclusion: Health care redesign facilitated identification of patients and implementation of ACP for chronic respiratory patients. Evaluation of patient-related outcomes and health care utilisation will be undertaken following formal validation of the HOMR tool in respiratory patients.
- 1 September 2017
- Published by European Respiratory Society (ERS)
- Vol. 50 (suppl 61) , PA603
Advance Care Planning (ACP) for end stage respiratory patients identified using the Hospital One year Mortality Rating (HOMR) tool
Background: Advance Care Planning (ACP) results in improved use of resources and patient outcomes. Inadequate ACP undermines self-determination and risks ineffective treatment. We reviewed records of patients enrolled in a respiratory outreach program at a University hospital in Sydney, Australia. At baseline none had an Advance Care Plan in the electronic medical records (eMR). Objectives: To improve end of life planning and outcomes for patients with advanced chronic lung conditions. Methods: We used healthcare redesign methodology including: literature review; process mapping; patient/carer interviews; staff surveys; focus groups; data abstraction and analysis. Five focus areas were identified and solutions mapped. Results: Patients, carers and clinicians were willing to be engaged in ACP. Application of the HOMR tool mapped risk of death within 12 months in this population (n=183, median 13.6%, range 0.2 - 91.1%; 16 patients had a 50% or greater risk). A standardised process was developed colaboratively with the multidisciplinary team comprising changed work practices, evidence based staff training, engagement with primary care and eMR solutions. At 6 months 11 advance care plans were completed. Conclusion: Health care redesign facilitated identification of patients and implementation of ACP for chronic respiratory patients. Evaluation of patient-related outcomes and health care utilisation will be undertaken following formal validation of the HOMR tool in respiratory patients.
- 1 March 2015
- Published by Oxford University Press (OUP)
- p. 49-64
The epidemiology of death and symptoms: planning for population-based palliative care
Despite the advances of modern medicine, many illnesses continue to evade cure. Chronic, progressive, incurable illness is a major cause of disability, distress, suffering, and, ultimately, death. This is true for many causes of cancer, progressive neurological disorders, AIDS, and other disorders of vital organs. Progressive chronic diseases of this ilk are most common in late adulthood and old age, but they occur in all ages. When cure is not possible, as often it is not, the relief of suffering is the cardinal goal of medicine. The clinical imperative to relive suffering requires a nuanced understanding of the factors that contribute to suffering and the interaction between the distress of the patient, family members, and health-care providers. This chapter reviews those concepts and offers an approach to the evaluation of suffering for patients requiring palliative care.
- 1 March 2015
- Published by Oxford University Press (OUP)
- p. 49-64
The epidemiology of death and symptoms: planning for population-based palliative care
Despite the advances of modern medicine, many illnesses continue to evade cure. Chronic, progressive, incurable illness is a major cause of disability, distress, suffering, and, ultimately, death. This is true for many causes of cancer, progressive neurological disorders, AIDS, and other disorders of vital organs. Progressive chronic diseases of this ilk are most common in late adulthood and old age, but they occur in all ages. When cure is not possible, as often it is not, the relief of suffering is the cardinal goal of medicine. The clinical imperative to relive suffering requires a nuanced understanding of the factors that contribute to suffering and the interaction between the distress of the patient, family members, and health-care providers. This chapter reviews those concepts and offers an approach to the evaluation of suffering for patients requiring palliative care.
- Open Access
- 1 June 2013
- Published by BMJ in BMJ Supportive & Palliative Care
- Vol. 3 (2) , 256.2-256
ADVANCE CARE PLANNING WHO, WHEN AND WHERE. WHAT IS THE EVIDANCE TO SUPPORT THE CALL TO PLAN EARLY
Background Eighty-six per cent of Australians state a preference to die peacefully at home, in fact only around 20% die at home. What is the evidence that supports our approach to Advance Care Planning? What populations can be effectively targeted? What are the necessary components that comprise and accompany an effective ACP? What are the barriers? What are the important outcomes? How do we provide confidence in the availability of care outside the acute setting to permit the ideal of staff and families/carers following an ACP and avoiding crisis transfers? What is the role of the acute setting in ACP? Aim To review the evidence that supports a co-ordianated approach to ACP. Methods This presentation is a systematic review of the evidence that informs our approach to ACP in primary and secondary health care settings Results The evidence to support a comprehensive, tailored approach to identifying patients who might benefit from ACP, an approach to symptom management and carer support in a primary health care setting with appropriate co-ordination with specialist palliative care will be presented. Discussion Only 4% of decedents do not have an the Emergency Department (ED) Presentation in the last year of life. The trajectory of chronic illness and co-morbidity determine that ED presentations provide the opportunity to identify patients who might benefit from ACP how can this inform our approach? Conclusion Advance Care Planning has been associated with improved patient outcomes. The suggested approach supports the aspiration to Plan EARLY, and identifies appropriate target populations and outcome measures.
- 1 June 2013
- Published by BMJ in BMJ Supportive & Palliative Care
- Vol. 3 (2) , 256.2-256
Open AccessADVANCE CARE PLANNING WHO, WHEN AND WHERE. WHAT IS THE EVIDANCE TO SUPPORT THE CALL TO PLAN EARLY
Background Eighty-six per cent of Australians state a preference to die peacefully at home, in fact only around 20% die at home. What is the evidence that supports our approach to Advance Care Planning? What populations can be effectively targeted? What are the necessary components that comprise and accompany an effective ACP? What are the barriers? What are the important outcomes? How do we provide confidence in the availability of care outside the acute setting to permit the ideal of staff and families/carers following an ACP and avoiding crisis transfers? What is the role of the acute setting in ACP? Aim To review the evidence that supports a co-ordianated approach to ACP. Methods This presentation is a systematic review of the evidence that informs our approach to ACP in primary and secondary health care settings Results The evidence to support a comprehensive, tailored approach to identifying patients who might benefit from ACP, an approach to symptom management and carer support in a primary health care setting with appropriate co-ordination with specialist palliative care will be presented. Discussion Only 4% of decedents do not have an the Emergency Department (ED) Presentation in the last year of life. The trajectory of chronic illness and co-morbidity determine that ED presentations provide the opportunity to identify patients who might benefit from ACP how can this inform our approach? Conclusion Advance Care Planning has been associated with improved patient outcomes. The suggested approach supports the aspiration to Plan EARLY, and identifies appropriate target populations and outcome measures.
- 13 September 2010
- Published by SAGE Publications in Palliative Medicine
- Vol. 24 (6) , 561-565
Single Question in Delirium (SQiD): testing its efficacy against psychiatrist interview, the Confusion Assessment Method and the Memorial Delirium Assessment Scale
In this study we address the research question; How sensitive is a single question in delirium case finding? Of 33 ‘target’ admissions, consent was obtained from 21 patients. The single question: ‘Do you think [name of patient] has been more confused lately?’ was put to friend or family. Results of the Single Question in Delirium (SQiD) were compared to psychiatrist interview (ΨI) which was the reference standard. The Confusion Assessment Method (CAM) and two other tools were also applied. Compared with ΨI, the SQiD achieved a sensitivity and specificity of 80% (95% CI 28.3—99.49%) and 71% (41.90—91.61%) respectively. The CAM demonstrated a negative predictive value (NPV) of 80% (51.91—95.67%) and the SQiD showed a NPV of 91% (58.72—99.77%). Kappa correlation of SQiD with the ΨI was 0.431 (p = 0.023). The CAM had a kappa value of 0.37 (p = 0.050). A further important finding in our study was that the CAM had only 40% sensitivity in the hands of minimally trained clinical users. Conclusion: The SQiD demonstrates potential as a simple clinical tool worthy or further investigation.
- 13 September 2010
- Published by SAGE Publications in Palliative Medicine
- Vol. 24 (6) , 561-565
Single Question in Delirium (SQiD): testing its efficacy against psychiatrist interview, the Confusion Assessment Method and the Memorial Delirium Assessment Scale
In this study we address the research question; How sensitive is a single question in delirium case finding? Of 33 ‘target’ admissions, consent was obtained from 21 patients. The single question: ‘Do you think [name of patient] has been more confused lately?’ was put to friend or family. Results of the Single Question in Delirium (SQiD) were compared to psychiatrist interview (ΨI) which was the reference standard. The Confusion Assessment Method (CAM) and two other tools were also applied. Compared with ΨI, the SQiD achieved a sensitivity and specificity of 80% (95% CI 28.3—99.49%) and 71% (41.90—91.61%) respectively. The CAM demonstrated a negative predictive value (NPV) of 80% (51.91—95.67%) and the SQiD showed a NPV of 91% (58.72—99.77%). Kappa correlation of SQiD with the ΨI was 0.431 (p = 0.023). The CAM had a kappa value of 0.37 (p = 0.050). A further important finding in our study was that the CAM had only 40% sensitivity in the hands of minimally trained clinical users. Conclusion: The SQiD demonstrates potential as a simple clinical tool worthy or further investigation.
- 1 January 2010
- Published by Oxford University Press (OUP)
3.2 The epidemiology of the end-of-life experience
- 1 January 2010
- Published by Oxford University Press (OUP)
3.2 The epidemiology of the end-of-life experience